Preclinical News and Research

RSS

NIH awards Novavax a SBIR grant for respiratory syncytial virus vaccine research

Novavax, Inc. announced today that it has received a Small Business and Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant from the NIAID is to support a segment of the Company's preclinical research program for the respiratory syncytial virus (RSV) particle-based vaccine.

14 Oct 2009

Sequella receives Phase 1 SBIR grant for developing SQ641

Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.

13 Oct 2009

Compugen, Bayer Schering Pharma sign collaboration agreement for tumor research

Compugen Ltd. announced today that they have signed a collaboration agreement with Bayer Schering Pharma AG, Germany covering the further evaluation of a Compugen discovered tumor target and its splice variants.

13 Oct 2009

SANUWAVE presents findings on extracorporeal shock wave stimulation of osteoprogenitor cells

SANUWAVE, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reported that scientific findings titled “Extracorporeal Shock Wave Stimulation of Osteoprogenitor Cells” were presented at the 2009 International Bone-Tissue-Engineering Congress (“Bone-Tec”) in Hannover, Germany, which was held October 9-11, 2009.

13 Oct 2009

SAFC Pharma expands contract manufacturing services

SAFC Pharma®, a business segment of SAFC®, a member of the Sigma-Aldrich® Group, today announced the completion of an addition to its Carlsbad, Calif., facility that expands the Company's contract manufacturing services for its late phase and commercial clients.

13 Oct 2009

Cognitive abilites other than memory may decline prior to clinical diagnosis in patients with Alzheimer's disease

Cognitive abilities other than memory, including visuospatial skills needed to perceive relationships between objects, may decline years prior to a clinical diagnosis in patients with Alzheimer's disease, according to a report in the October issue of Archives of Neurology, one of the JAMA/Archives journals.

13 Oct 2009

Ethicon Endo-Surgery launches energy delivery devices at the 95th ACS Annual Clinical Congress

Ethicon Endo-Surgery, Inc., today unveiled its broad portfolio of energy delivery devices at the 95th Annual Clinical Congress of the American College of Surgeons (ACS).

12 Oct 2009

Results of Phase 2a clinical trial of DR Cysteamine announced by Raptor Pharmaceutical

Raptor Pharmaceutical Corp., announced positive findings from the completed treatment phase of its open-label Phase 2a clinical trial of delayed-release cysteamine bitartrate ("DR Cysteamine") in adolescent patients with non-alcoholic steatohepatitis ("NASH"), a progressive form of liver disease believed to affect 2% to 5% of the U.S. population.

12 Oct 2009

Selexis and Irvine Scientificti to jointly present results of recent collaborative effort

Selexis SA and Irvine Scientific Inc. announced today plans to jointly present results of a recent collaborative effort combining the Selexis SURE Cell Line Development Programs(TM) and the Irvine IS CHO Culture System, demonstrating the rapid production of gram quantities of monoclonal antibodies from stable CHO production cell lines.

12 Oct 2009

RXi Pharmaceuticals presents new preclinical data from its advanced RNAi therapeutic platform

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced the presentation of new preclinical data from its advanced RNAi therapeutic platform at its Annual Investor Event held in New York City on Monday, October 5, 2009.

9 Oct 2009

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Plexxikon Inc. today announced that dosing of cancer patients with PLX3397 has started in a Phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating multiple diseases, including metastatic cancer and rheumatoid arthritis.

9 Oct 2009

Keryx Biopharmaceuticals commences Phase 2 clinical study evaluating KRX-0401 for Chronic Lymphocytic Leukemia

Keryx Biopharmaceuticals, Inc. announced today the initiation of a Phase 2 clinical study to evaluate KRX-0401 (perifosine) as a single agent treatment for relapsed or refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL).

8 Oct 2009

Omeros announces the pricing of its initial public offering of 6.82 million shares

Omeros Corporation today announced the pricing of its initial public offering of 6.82 million shares of its common stock at a price of $10.00 per share. The underwriters have the option to purchase up to an additional 1.02 million shares to cover over-allotments, if any.

8 Oct 2009

Reverse Medical Corporation commences human use of its ReStore Microcatheter

Reverse Medical Corporation announced today they have initiated human use of their ReStore™ Microcatheter for reestablishing blood flow in the Neurovasculature. The device was successfully used in an acute ischemic stroke patient in Germany.

8 Oct 2009

Mimetogen Pharmaceuticals completes its equity financing

Mimetogen Pharmaceuticals Inc. ("Mimetogen"), a privately held drug development company announced today that it has successfully completed an equity financing, co-led by Boston-based VIMAC Milestone Medica Fund and Montréal-based iNovia Capital.

8 Oct 2009

Peregrine Pharmaceuticals establishes a new Anti-Viral Research Group

Peregrine Pharmaceuticals, Inc. today announced that it has established a new Anti-Viral Research Group in its R&D organization.

7 Oct 2009

Allos Therapeutics to raise $99.4 million through sale of its common stock

Allos Therapeutics, Inc. today announced the pricing of an underwritten public offering of 14,000,000 primary shares of its common stock at a public offering price of $7.10 per share.

7 Oct 2009

GlobeImmune to present an abstract of GI-5005 drug at AASLD's annual meeting

GlobeImmune Inc. today announced that a late breaking abstract related to GI-5005, its investigational hepatitis C virus (HCV) product candidate, has been accepted for presentation at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place Oct. 31 through Nov. 4, 2009, in Boston, Mass.

7 Oct 2009

PSI-879 nominated as second development candidate for treating HCV infection

Pharmasset, Inc. announced today the nomination of PSI-352879 (PSI-879) as a second development candidate from two series of purine analogs for the treatment of chronic hepatitis C virus (HCV) infection.

7 Oct 2009

African leaders gather to discuss ways to bolster continent's drug, diagnostic development

Business Day examines efforts currently underway in Africa to bolster the continent's ability to develop new drugs and diagnostics.

7 Oct 2009

Preclinical News and Research

NIH awards Novavax a SBIR grant for respiratory syncytial virus vaccine research

Sequella receives Phase 1 SBIR grant for developing SQ641

Compugen, Bayer Schering Pharma sign collaboration agreement for tumor research

SANUWAVE presents findings on extracorporeal shock wave stimulation of osteoprogenitor cells

SAFC Pharma expands contract manufacturing services

Cognitive abilites other than memory may decline prior to clinical diagnosis in patients with Alzheimer's disease

Ethicon Endo-Surgery launches energy delivery devices at the 95th ACS Annual Clinical Congress

Results of Phase 2a clinical trial of DR Cysteamine announced by Raptor Pharmaceutical

Selexis and Irvine Scientificti to jointly present results of recent collaborative effort

RXi Pharmaceuticals presents new preclinical data from its advanced RNAi therapeutic platform

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Keryx Biopharmaceuticals commences Phase 2 clinical study evaluating KRX-0401 for Chronic Lymphocytic Leukemia

Omeros announces the pricing of its initial public offering of 6.82 million shares

Reverse Medical Corporation commences human use of its ReStore Microcatheter

Mimetogen Pharmaceuticals completes its equity financing

Peregrine Pharmaceuticals establishes a new Anti-Viral Research Group

Allos Therapeutics to raise $99.4 million through sale of its common stock

GlobeImmune to present an abstract of GI-5005 drug at AASLD's annual meeting

PSI-879 nominated as second development candidate for treating HCV infection

African leaders gather to discuss ways to bolster continent's drug, diagnostic development

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News